Author: "Bodrogi I." - Searchworks@Jio Institute Digital Library Search Results

Your search keyword '"Bodrogi I."' showing total 233 results

Start Over Author "Bodrogi I."

233 results on '"Bodrogi I."'

1. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Author: von der Maase, H., primary, Hansen, S.W., additional, Roberts, J.T., additional, Dogliotti, L., additional, Oliver, T., additional, Moore, M.J., additional, Bodrogi, I., additional, Albers, P., additional, Knuth, A., additional, Lippert, C.M., additional, Kerbrat, P., additional, Sanchez Rovira, P., additional, Wersall, P., additional, Cleall, S.P., additional, Roychowdhury, D.F., additional, Tomlin, I., additional, Visseren-Grul, C.M., additional, and Conte, P.F., additional
Published: 2023
Full Text: View/download PDF

2. A Retrospective Analysis of the First 41 mCRPC Patients with Bone Pain Treated with Radium-223 at the National Institute of Oncology in Hungary

Author: Küronya, Zs, Sinkovics, I, Ágoston, P, Bíró, K, Bodrogi, I, Böde, I, Dank, M, Gyergyay, F, Vajdics, T, Kolonics, Zs, Nagyiványi, K, Rúzsa, Á, and Géczi, L
Published: 2017
Full Text: View/download PDF

3. A phase II multicentre study of irinotecan (CPT 11) in combination with cisplatin (CDDP) in metastatic or locally advanced penile carcinoma (EORTC PROTOCOL 30992)

Author: Theodore, C., Skoneczna, I., Bodrogi, I., Leahy, M., Kerst, J.M., Collette, L., Ven, K., Marréaud, S., and Oliver, R.D.T.
Published: 2008
Full Text: View/download PDF

4. Phase I study of TZT-1027, a novel synthetic dolastatin 10 derivative, for the treatment of patients with non-small cell lung cancer

Author: Horti, J., Juhasz, E., Monostori, Z., Maeda, K., Eckhardt, S., and Bodrogi, I.
Published: 2008
Full Text: View/download PDF

5. HER-2/neu as a Predictive Marker in a Population of Advanced Breast Cancer Patients Randomly Treated Either with Single-agent Doxorubicin or Single-agent Docetaxel

Author: Di Leo, A., Chan, S., Paesmans, M., Friedrichs, K., Pinter, T., Cocquyt, V., Murray, E., Bodrogi, I., Walpole, E., Lesperance, B., Korec, S., Crown, J., Simmonds, P., Von Minckwitz, G., Leroy, J.Y., Durbecq, V., Isola, J., Aapro, M., Piccart, M.J., and Larsimont, D.
Published: 2004
Full Text: View/download PDF

6. The Effect of Intravesical Mitomycin C on the Recurrence of Superficial (Ta–T1) Bladder Cancer. A Hungarian Multicenter Study

Author: Kondás, J., Kiss, L., Határ, A., Kiss, A., Lukács, T., Szeldeli, P., Törzsök, F., and Bodrogi, I.
Published: 1999
Full Text: View/download PDF

7. Significance of examination of prostate-specific antigen and prostate-specific antigen density in patients with prostatic hyperplasia and prostate cancer

Author: Romics, I., Frang, D., and Bodrogi, I.
Published: 1997
Full Text: View/download PDF

8. Results of salvage retroperitoneal lymphadenectomy (RLA) in the treatment of patients with nonseminomatous germ cell tumours remaining marker positive after inductive chemotherapy

Author: Kisbenedek, L., Bodrogi, I., Szeldeli, P., Baki, M., Tenke, P., and Horti, J.
Published: 1995
Full Text: View/download PDF

9. European consensus on diagnosis and treatment of germ cell cancer: a report of the European Germ Cell Cancer Consensus Group (EGCCCG)

Author: Schmoll, H.J., Souchon, R., Krege, S., Albers, P., Beyer, J., Kollmannsberger, C., Fossa, S.D., Skakkebaek, N.E., de Wit, R., Fizazi, K., Droz, J.P., Pizzocaro, G., Daugaard, G., de Mulder, P.H.M., Horwich, A., Oliver, T., Huddart, R., Rosti, G., Paz Ares, L., Pont, O., Hartmann, J.T., Aass, N., Algaba, F., Bamberg, M., Bodrogi, I., Bokemeyer, C., Classen, J., Clemm, S., Culine, S., de Wit, M., Derigs, H.G., Dieckmann, K.P., Flasshove, M., Garcia del Muro, X., Gerl, A., Germa-Lluch, J.R., Hartmann, M., Heidenreich, A., Hoeltl, W., Joffe, J., Jones, W., Kaiser, G., Klepp, O., Kliesch, S., Kisbenedek, L., Koehrmann, K.U., Kuczyk, M., Laguna, M.P., Leiva, O., Loy, V., Mason, M.D., Mead, G.M., Mueller, R.P., Nicolai, N., Oosterhof, G.O.N., Pottek, T., Rick, O., Schmidberger, H., Sedlmayer, F., Siegert, W., Studer, U., Tjulandin, S., von der Maase, H., Walz, P., Weinknecht, S., Weissbach, L., Winter, E., and Wittekind, C.
Published: 2004
Full Text: View/download PDF

10. Gemcitabine and Cisplatin Versus Methotrexate, Vinblastine, Doxorubicin, and Cisplatin in Advanced or Metastatic Bladder Cancer: Results of a Large, Randomized, Multinational, Multicenter, Phase III Study

Author: von der Maase, H., Hansen, S.W., Roberts, J.T., Dogliotti, L., Oliver, T., Moore, M.J., Bodrogi, I., Albers, P., Knuth, A., Lippert, C.M., Kerbrat, P., Sanchez Rovira, P., Wersall, P., Cleall, S.P., Roychowdhury, D.F., Tomlin, I., Visseren-Grul, C.M., and Conte, P.F.
Published: 2000

11. An international expanded-access programme of everolimus: addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor tyrosine-kinase inhibitor therapy

Author: Grünwald V., Karakiewicz P. . I, Bavbek S. . E, Miller K., Machiels J. P., Lee S. H., Larkin J., Bono P., Rha S. Y., Castellano D., Blank C. U., Knox J. J., Hawkins R., Anak O., Rosamilia M., Booth J., Pirotta N., Bodrogi I., REACT Study Group, included, DE PLACIDO, SABINO, Grünwald, V., Karakiewicz, P. . I., Bavbek, S. . E., Miller, K., Machiels, J. P., Lee, S. H., Larkin, J., Bono, P., Rha, S. Y., Castellano, D., Blank, C. U., Knox, J. J., Hawkins, R., Anak, O., Rosamilia, M., Booth, J., Pirotta, N., Bodrogi, I., REACT Study, Group, Included, and DE PLACIDO, Sabino
Published: 2012

12. Central and Eastern European experience with sutent from the expanded-access mRCC trial

Author: Vrdoljak, E, Bodrogi, I, Mardiak, J, Ciuleanu, TE, Gorbunova, V, Leyman, S, Zhang, K, and Torday, L
Subjects: mRCC
Abstract: Central and Eastern European experience with sutent from the expanded-access mRCC trial
Published: 2013

13. An international expanded-access programme of everolimus: Addressing safety and efficacy in patients with metastatic renal cell carcinoma who progress after initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor therapy

Author: Grünwald, V, Karakiewicz, P, Bavbek, S, Miller, K, Machiels, J, Lee, S, Larkin, J, Bono, P, Rha, S, Castellano, D, Blank, C, Knox, J, Hawkins, R, Anak, O, Rosamilia, M, Booth, J, Pirotta, N, Bodrogi, I, Romedi, M, Ferrandini, S, Rondinon, M, Pittman, K, Goldstein, D, Shapiro, J, Troon, S, Yip, D, Mainwaring, P, Zigeuner, R, Loidl, W, Greil, R, Schmidinger, M, De Grève, J, Rottey, S, Vermorken, J, Gil, T, Gennigens, C, Roumeguere, T, Barrios, C, Mathias, C, Assi, H, Hotte, S, Spadafora, S, Wood, L, Zalewski, P, Mackensie, M, Bjarnason, G, Lalancette, A, Chan, A, Higgins, B, North, S, Soulieres, D, Asselah, J, Sperlich, C, Miller, W, Yadav, S, El Maraghi, R, Godoy, J, Prausová, J, Katolicka, J, Petruzelka, L, Kiss, I, Lapela, M, Bergmann, L, Beck, J, Jäger, E, Kindler, M, Overkamp, F, Wirth, M, Hölzer, W, Gschwend, J, Stenzl, A, Gauler, T, Niederwieser, D, Marschner, N, Lück, A, Tessen, H, Eichelberg, C, Steiner, T, Goebell, P, Kettner, E, Bakhshandeh Bath, A, Wilhelm, M, Schmitz, S, Jacob, A, Bierer, S, Kube, U, Staehler, M, Engel, E, Frambach, M, Schellenberger, U, Albers, P, Simon, J, Gleissler, M, Klotz, T, Repp, R, Kröning, H, Westermann, J, Rebmann, U, Brehmer, B, Niederle, N, Grund, C, Verpoort, K, Fonara, P, Rassweiler, J, Bamias, A, Fountzilas, G, Razis, E, Mouratidou, D, Georgoulias, V, Samantas, E, Mangel, L, Szanto, J, Berger, R, Pe'Er, A, Sella, A, Ben Yosef, R, Nechushtan, H, Crinò, L, Bracarda, S, Ciuffreda, L, Graiff, C, Falcone, A, Roselli, M, Sternberg, C, Santoro, A, Ruggeri, E, Bearz, A, Venturini, M, Aglietta, M, Amadori, D, Di Costanzo, F, Bari, M, Gebbia, N, Conte, P, Bonetti, A, Bordonaro, R, Cascinu, S, Contu, A, Cruciani, G, Gasparro, D, Nardi, M, Lelli, G, Lo Re, G, Boccardo, F, Lorusso, V, Maiello, E, Manente, P, Passalacqua, R, Piantedosi, F, Porta, C, Sacco, C, Tondini, C, De Placido, S, Carteni, G, Dogliotto, L, Rosti, G, Milella, M, Roila, F, Amoroso, D, Farina, G, Al Khatib, H, Kim, T, Ahn, J, Lim, H, Chung, I, Kim, J, Chung, J, Ghosn, M, Shameseddine, A, Lugo, R, Cabrera, P, Osanto, S, Groenewegen, G, van den Eertwegh, F, van Herpen, C, Oosting, S, Soetekouw, P, Lilleby, W, Klepp, O, Guren, T, Alcedo, J, Karlov, P, Nosov, D, Roman, L, Rusakov, I, Bazarbashi, S, Toh, C, Mardiak, J, del Muro Solans, F, Ray, J, Mollins, J, Martinez, I, Gonzalez, B, Santasusana, M, Piqueras, M, Fuentes, J, Larriba, J, Caro, R, Garcia, A, Aparicio, L, Lopez, N, Aragon, V, Morales, C, Figueiras, M, Ibanez, J, Billalabeitia, G, Estrada, E, Arranz, J, Sorrosal, J, Lozano, A, de Villena, M, Espinosa, E, Lopez, R, Perez, J, Laurell, A, Stierner, U, Cwikiel, M, Borner, M, Dietrich, P, Rothermundt, C, Pu, Y, Chang, Y, Ou, Y, Chuang, C, Liao, Y, Srimuninnimit, V, Sriuranpong, V, Buyukberber, S, Yalcin, B, Goker, E, Yalcin, S, Geldart, T, Wagstaff, J, Nicholson, S, Chowdhury, S, Bahl, A, Jones, R, Azzabi, A, Chao, D, Fife, K, Mead, G, Nathan, P, Pandha, H, Hajdenberg, J, Gabrail, N, Nimeh, N, Logan, T, Flaig, T, Schraeder, R, Rini, B, O'Rourke, M, Alemany, C, Kessinger, A, Amin, A, Arriaga, M, Rodriguez, J, Gauler, Thomas (Beitragende*r), RS: GROW - R3 - Innovative Cancer Diagnostics & Therapy, Interne Geneeskunde, and Laboratory of Molecular and Medical Oncology
Subjects: Nephrology, Oncology, Male, Cancer Research, mTOR inhibitor, Settore MED/06 - Oncologia Medica, Medizin, Advanced kidney cancer, RAD001, REACT, 0302 clinical medicine, Renal cell carcinoma, Receptors, 80 and over, Treatment Failure, Neoplasm Metastasis, Aged, 80 and over, 0303 health sciences, Vascular Endothelial Growth Factor, Sirolimus, Young Adult, Antineoplastic Agents, Humans, Aged, Immunosuppressive Agents, Protein Kinase Inhibitors, Receptors, Vascular Endothelial Growth Factor, Kidney Neoplasms, Adult, Carcinoma, Renal Cell, Middle Aged, Female, 3. Good health, 030220 oncology & carcinogenesis, Safety, medicine.drug, medicine.medical_specialty, SECOND LINE THERPAY, Second-line therapy, Everolimus, 03 medical and health sciences, Internal medicine, medicine, Adverse effect, 030304 developmental biology, business.industry, Carcinoma, Renal Cell, medicine.disease, Surgery, Clinical trial, Expanded access, business, Kidney cancer
Abstract: BACKGROUND AND OBJECTIVES: The RECORD-1 trial established the clinical benefit of everolimus in patients with metastatic renal cell carcinoma (mRCC) after failure of initial vascular endothelial growth factor receptor-tyrosine kinase inhibitor (VEGFr-TKI) therapy. The REACT (RAD001 Expanded Access Clinical Trial in RCC) study was initiated to address an unmet medical need by providing everolimus prior to commercial availability, and also to further assess the safety and efficacy of everolimus in patients with VEGFr-TKI-refractory mRCC. PATIENTS AND METHODS: REACT (Clinicaltrials.gov: NCT00655252) was a global, open-label, expanded-access programme in patients with mRCC who were intolerant of, or who had progressed on or after stopping treatment with, any available VEGFr-TKI therapy. Patients received everolimus 10mg once daily, with dose and schedule modifications allowed for toxicity. Patients were closely monitored for the development of serious and grades 3/4 adverse events (AEs). Response was assessed by RECIST every 3months for the first year and every 6months thereafter. RESULTS: A total of 1367 patients were enroled. Safety findings and tumour responses were consistent with those observed in RECORD-1, with no new safety issues identified. The most commonly reported serious AEs were dyspnoea (5.0%), pneumonia (4.7%) and anaemia (4.1%), and the most commonly reported grades 3/4 AEs were anaemia (13.4%), fatigue (6.7%) and dyspnoea (6.5%). Best overall response was stable disease in 51.6% and partial response in 1.7% of patients. Median everolimus treatment duration was 14weeks. CONCLUSION: Everolimus is well tolerated in patients with mRCC and demonstrates a favourable risk-benefit ratio.
Published: 2012

14. Komplikationen der retroperitonealen Lymphadenektomie

Author: Balogh, F., primary, Kisbenedek, L., additional, Szeldeli, P., additional, and Bodrogi, I., additional
Published: 1987
Full Text: View/download PDF

15. The Y deletion gr/gr and susceptibility to testicular germ cell tumor

Author: Nathanson, KL, Kanetsky, PA, Hawes, R, Vaughn, DJ, Letrero, R, Tucker, K, Friedlander, M, Phillips, KA, Hogg, D, Jewett, MAS, Lohynska, R, Daugaard, G, Richard, S, Chompret, A, Bonati-Pellie, C, Heidenreich, A, Olah, E, Geczi, L, Bodrogi, I, Ormiston, WJ, Daly, PA, Oosterhuis, Wolter, Gillis, Ad, Looijenga, LHJ (Leendert), Guilford, P, Fossa, SD, Heimdal, K, Tjulandin, SA, Liubchenko, L, Stoll, H, Weber, W, Huddart, R, Crockford, GP, Forman, D, Oliver, DT, Einhorn, L, Weber, BL, Kramer, J (Judith), McMaster, M, Greene, MH, Pike, M, Cortessis, V, Chen, C (Christopher Li Hsian), Schwartz, SM, Bishop, DT, Easton, DF, Stratton, MR, Rapley, EA, Pathology, and Immunology
Published: 2005

16. Modern diagnostics and therapy of seminoma

Author: Ésik, Olga, Baki, Márta, Gundy, S., Bodrogi, I., and Trón, Lajos
Subjects: Orvostudományok, Klinikai orvostudományok
Abstract: LB
Published: 1999

17. Filgrastim during combination chemotherapy of patients with poor-prognosis metastatic germ cell malignancy

Author: Fossa, SD, Kaye, SB, Mead, GM, Cullen, MH, de Wit, Ronald, Bodrogi, I, van Groeningen, CJ, de Mulder, PHM, Stenning, SP, Lallemand, E, de Prijck, L, Collette, L, and Medical Oncology
Subjects: Experimental diagnostics and therapy of malignancies
Abstract: Item does not contain fulltext
Published: 1998

18. Experience with Single Agent Adjuvant Carboplatin for Stage I Seminoma – A Retrospective Analysis

Author: Nemeth, H., primary, Küronya, Z., additional, Bíró, K., additional, Bodrogi, I., additional, and Géczi, L., additional
Published: 2012
Full Text: View/download PDF

19. Impact of Cabazitaxel (CBZ) + Prednisone (P; CBZP) on Overall Survival (OS) At 2 Yrs and in Patients (PTS) with Aggressive Disease: Post-Hoc Analyses of Tropic Trial

Author: Oudard, S., primary, de Bono, J.S., additional, Özgüroglu, M., additional, Hansen, S., additional, Machiels, J., additional, Kocak, I., additional, Gravis, G., additional, Bodrogi, I., additional, Shen, L., additional, and Sartor, A.O., additional
Published: 2012
Full Text: View/download PDF

20. Everolimus in patients with metastatic renal cell carcinoma (mRCC) who are intolerant of or have progressed after prior vascular endothelial growth factor receptor–tyrosine kinase inhibitor (VEGFr-TKI) therapy: An international expanded access program (EAP).

Author: Grunwald, V., primary, Bodrogi, I., additional, Miller, K., additional, Machiels, J. H., additional, Lee, S., additional, Chowdhury, S., additional, Yuan, R., additional, Rosamilia, M., additional, Booth, J. L., additional, and Karakiewicz, P. I., additional
Published: 2011
Full Text: View/download PDF

21. Decreased toxicity schedule of suitinib in renal cell cancer: 2 weeks on/1 week off

Author: Gyergyay, F., primary, Nagyványi, K., additional, and Bodrogi, I., additional
Published: 2009
Full Text: View/download PDF

22. A RANDOMISED DOUBLE-BLIND PLACEBO-CONTROLLED PHASE II STUDY OF VANDETANIB PLUS DOCETAXEL / PREDNISOLONE IN PATIENTS WITH HORMONE-REFRACTORY PROSTATE CANCER

Author: Horti, J., primary, Widmark, A., additional, Stenzl, A., additional, Turesson, I., additional, Federico, M.H., additional, Abratt, R.P., additional, Sanders, N., additional, Pover, G.M., additional, and Bodrogi, I., additional
Published: 2008
Full Text: View/download PDF

23. SATRAPLATIN (S) INCREASES PROGRESSION-FREE SURVIVAL (PFS) AND DELAYS PAIN PROGRESSION IN PATIENTS (PTS) WITH HORMONE REFRACTORY PROSTATE CANCER (HRPC) THAT HAVE PROGRESSED AFTER PRIOR DOCETAXEL

Author: Sternberg, N., primary, Sartor, O.A., additional, Petrylak, D.P., additional, Witjes, F., additional, Bodrogi, I., additional, Harper, P., additional, James, N., additional, Demkov, T., additional, Eymard, J-C., additional, and Wirth, M., additional
Published: 2008
Full Text: View/download PDF

24. 4010 POSTER Satraplatin increases progression-free survival (PFS) and delays pain progression in hormone refractory prostate cancer (HRPC): Results of SPARC, an international phase III trial with 950 patients

Author: Sternberg, C., primary, Sartor, O., additional, Petrylak, D., additional, Witjes, J.A., additional, Bodrogi, I., additional, Harper, P., additional, Droz, J.P., additional, and James, N., additional
Published: 2007
Full Text: View/download PDF

25. 4502 ORAL Phase 2 study of irinotecan and cisplatin in epidermoid carcinoma of the penis (EORTC 30992)

Author: Theodore, C., primary, Skoneczna, I., additional, Bodrogi, I., additional, Leahy, M., additional, Chester, J., additional, Kerst, J.M., additional, Collette, L., additional, Ven, K., additional, Marréaud, S., additional, and Oliver, R.T.D., additional
Published: 2007
Full Text: View/download PDF

26. Spontaneous otoacoustic emissions (SOAE) changes in testicular cancer patients treated with cisplatin: A pilot study of whether the acute ototoxic effect of cisplatin treatment can be detected

Author: Biro, K., primary, Noszek, L., additional, Prekopp, P., additional, Vehovszky, K., additional, Nemeth, E., additional, Nagyivanyi, K., additional, Geczi, L., additional, Gaudi, I., additional, and Bodrogi, I., additional
Published: 2007
Full Text: View/download PDF

27. Characteristics and Risk Factors of Cisplatin-Induced Ototoxicity in Testicular Cancer Patients Detected by Distorsion Product Otoacoustic Emission

Author: Biro, K., primary, Noszek, L., additional, Prekopp, P., additional, Nagyiványi, K., additional, Géczi, L., additional, Gaudi, I., additional, and Bodrogi, I., additional
Published: 2006
Full Text: View/download PDF

28. Comparison of Interleukin-2, Interferon-alpha, 5-fluorouracyl combination and Interferon-alpha, vinblastin treatment in metastatic renal cell cancer

Author: Gyergyay, F., primary, Rathonyi, E., additional, Biro, K., additional, Nagyivanyi, K., additional, and Bodrogi, I., additional
Published: 2005
Full Text: View/download PDF

29. Characteristics and risk factors of cisplatin induced ototoxicity in testicular cancer patients, detected by distortion product otoacustic emmision (DPOAE)

Author: Biro, K., primary, Noszek, L., additional, Prekopp, P., additional, Nagyiványi, K., additional, Géczi, L., additional, Gaudi, I., additional, and Bodrogi, I., additional
Published: 2005
Full Text: View/download PDF

30. A multicenter phase III comparison of docetaxel (D) + prednisone (P) and mitoxantrone (MTZ) + P in patients with hormone-refractory prostate cancer (HRPC)

Author: Eisenberger, M. A., primary, De Wit, R., additional, Berry, W., additional, Bodrogi, I., additional, Pluzanska, A., additional, Chi, K., additional, Oudard, S., additional, Christine, T., additional, James, N., additional, and Tannock, I., additional
Published: 2004
Full Text: View/download PDF

31. Antitumor activity and pharmacology of TT-232 (a novel somatostatin structural derivative) in malignant melanoma patients

Author: Gyergyay, F., primary, Gödény, M., additional, Sármay, G., additional, Kralovanszky, J., additional, Papp, E., additional, Gergye, M., additional, Vincze, B., additional, Kéri, G., additional, and Bodrogi, I., additional
Published: 2004
Full Text: View/download PDF

32. Somatic mutations of KIT in familial testicular germ cell tumours

Author: Rapley, E A, primary, Hockley, S, additional, Warren, W, additional, Johnson, L, additional, Huddart, R, additional, Crockford, G, additional, Forman, D, additional, Leahy, M G, additional, Oliver, D T, additional, Tucker, K, additional, Friedlander, M, additional, Phillips, K-A, additional, Hogg, D, additional, Jewett, M A S, additional, Lohynska, R, additional, Daugaard, G, additional, Richard, S, additional, Heidenreich, A, additional, Geczi, L, additional, Bodrogi, I, additional, Olah, E, additional, Ormiston, W J, additional, Daly, P A, additional, Looijenga, L H J, additional, Guilford, P, additional, Aass, N, additional, Fosså, S D, additional, Heimdal, K, additional, Tjulandin, S A, additional, Liubchenko, L, additional, Stoll, H, additional, Weber, W, additional, Einhorn, L, additional, Weber, B L, additional, McMaster, M, additional, Greene, M H, additional, Bishop, D T, additional, Easton, D, additional, and Stratton, M R, additional
Published: 2004
Full Text: View/download PDF

33. 883 Expression and clinical relevance of the lung resistance protein in germ cell testicular tumours

Author: Mandoky, L., primary, Geczi, L., additional, Doleschall, Z., additional, Bodrogi, I., additional, Csuka, O., additional, and Bak, M., additional
Published: 2003
Full Text: View/download PDF

34. 992 Human phase II/A study of a novel somatostatin analogue, TT-232 in malignant melanoma patients

Author: Gyergyay, F., primary, Gödény, M., additional, Szüts, T., additional, Kéri, Gy., additional, Sármay, G., additional, and Bodrogi, I., additional
Published: 2003
Full Text: View/download PDF

35. A PET study on the characterization of partially reversible radiogenic lower motor neurone disease

Author: Ésik, O, primary, Lengyel, Z, additional, Sáfrány, G, additional, Vönöczky, K, additional, Ágoston, P, additional, Székely, J, additional, Lengyel, E, additional, Márián, T, additional, Trón, L, additional, and Bodrogi, I, additional
Published: 2002
Full Text: View/download PDF

36. PET reveals increased metabolic activity of the spinal cord after partial recovery from radiation myelopathy

Author: Esik, O., primary, Bodrogi, I., additional, Csere, T., additional, Safrany, G., additional, Vonoczky, K., additional, and Tron, L., additional
Published: 2001
Full Text: View/download PDF

37. Long term effect of oral testosterone substitution therapy on bone mineral density and hormone profil in patients with bilateral testicular cancer

Author: Horti, J., primary, Petranyi, A., additional, Forgacs, S., additional, and Bodrogi, I., additional
Published: 2001
Full Text: View/download PDF

38. Clinical characteristics, treatment and outcome of patients (pts) with bilateral testicular germ cell tumors (BTGCT)

Author: Geczi, L., primary, Gomez, F., additional, Bak, M., additional, and Bodrogi, I., additional
Published: 2001
Full Text: View/download PDF

39. Environmental or hereditary risk of cancer in testicular tumor patients?

Author: Gundy, S., primary, Babosa, M., additional, Baki, M., additional, and Bodrogi, I., additional
Published: 2001
Full Text: View/download PDF

40. A randomized phase II trial assessing irinotecan (IRI) and 5FU/folinic acid (LV), “Mayo regimen”, in first line palliative chemotherapy patients (pts) with metastatic colorectal cancer (MCRC)

Author: Pozzo, C., primary, Pyrhönen, S., additional, Bodrogi, I., additional, Szanto, J., additional, Kamica-Mlodkowska, H., additional, Starkammar, H., additional, Izso, J., additional, Hansen, P., additional, Kjaer, M., additional, Noël, N., additional, Gruia, G., additional, and Barone, C., additional
Published: 1999
Full Text: View/download PDF

41. Testicular self-examination (TSE) and testicular ultrasound (TUS) assisted follow-up for the early detection of secondary testicular tumors (STT)

Author: Géczi, L., primary and Bodrogi, I., additional
Published: 1999
Full Text: View/download PDF

42. Differential Expression of Glutathione S-Transferases in Germ Cell Tumors of Human Testes

Author: Institoris, E., primary, Eid, H., additional, Bodrogi, I., additional, and Bak, M., additional
Published: 1999
Full Text: View/download PDF

43. Letrozole, a new oral aromatase inhibitor: Randomised trial comparing 2.5 mg daily, 0.5 mg daily and aminoglutethimide in postmenopausal women with advanced breast cancer

Author: Gershanovich, M., primary, Chaudri, H.A., additional, Campos, D., additional, Lurie, H., additional, Bonaventura, A., additional, Jeffrey, M., additional, Buzzi, F., additional, Bodrogi, I., additional, Ludwig, H., additional, Reichardt, P., additional, O’Higgins, N., additional, Romieu, G., additional, Friederich, P., additional, and Lassus, M., additional
Published: 1998
Full Text: View/download PDF

44. Intensive induction-sequential chemotherapy with BOP/VIP-B compared with treatment with BEP/EP for poor-prognosis metastatic nonseminomatous germ cell tumor: a Randomized Medical Research Council/European Organization for Research and Treatment of Cancer study.

Author: Kaye, S B, primary, Mead, G M, additional, Fossa, S, additional, Cullen, M, additional, deWit, R, additional, Bodrogi, I, additional, van Groeningen, C, additional, Sylvester, R, additional, Collette, L, additional, Stenning, S, additional, De Prijck, L, additional, Lallemand, E, additional, and deMulder, P, additional
Published: 1998
Full Text: View/download PDF

45. Multicenter comparison of intravenous granlsetron (G) alone or In combination with dexamethasone (GD) in the prevention of nausea and vomiting associated with moderate and highly emetogenic chemotherapy (CH) — The Hungarian experience

Author: Géozi, L., primary, László, Gy., additional, Juhos, É, additional, Károlyi, É, additional, Bodrogi, I., additional, and Telekes, A., additional
Published: 1997
Full Text: View/download PDF

46. Allele loss of tumour suppressor genes on chromosome 17 in human testicular germ cell tumours

Author: vanderLooij, M, primary, Eid, H, additional, Bak, M, additional, Bodrogi, I, additional, and Olah, E, additional
Published: 1996
Full Text: View/download PDF

47. 5 P - Is P 53 expression, detected by immunohistochemistry, an important parameter of response to treatment in testis cancers?

Author: Eid, H., primary, Bodrogi, I., additional, and Bak, M., additional
Published: 1996
Full Text: View/download PDF

48. Multidrug resistance of testis carcinomas

Author: Bak, M, primary, Nicola, H E, additional, Bodrogi, I, additional, and Oláh, E, additional
Published: 1994
Full Text: View/download PDF

49. A study of children, fathered by men treated for testicular cancer, conceived before, during, and after chemotherapy

Author: Babosa, M., primary, Baki, M., additional, Bodrogi, I., additional, and Gundy, S., additional
Published: 1994
Full Text: View/download PDF

50. Persistence of Chromosomal Aberrations in Blood Lymphocytes of Testicular Cancer Patients

Author: Gundy, S., primary, Baki, M., additional, Bodrogi, I., additional, and Czeizel, A., additional
Published: 1992
Full Text: View/download PDF

Catalog

Books, media, physical & digital resources

See catalog results

Searchworks

Select search scope, currently: Articles Catalog books, media & more in Jio Institute collections Articles journal articles & other e-resources

Search

Search Constraints

Refine your results

Search Limiters

Topic

Publication Year Range

Language

Publication Type

Journal

Region

Database

Publisher

233 results on '"Bodrogi I."'

Search Results

Catalog

Select search scope, currently: Articles

Catalog

books, media & more in Jio Institute collections

Articles

journal articles & other e-resources